Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Adicet Bio, Inc. (TORC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 REDWOOD CITY, Calif. & BOSTON – August 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023. &#x..."
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Adicet Announces Appointment of Katie Peng to the Board of Directors REDWOOD CITY, Calif. & BOSTON – July 11, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors. “We are delighted to welcome Katie to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Her proven success as a commercial leader in both the U.S. and globally will be particularly valuable to Adicet as we advance ADI-001 and our pipeline of allogeneic gamma delta T cell therapy candidates in hematologic and solid tumors.” “I am pleased to join the Adicet Board at this exciting time for th..."
06/05/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SIXTH AMENDMENTTO"
05/18/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy 26th Annual Meeting ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and durability within a solid tumor microenvironment ADI-270 demonstrated potent anti-tumor activity in CD70+ cancers and improved resilience to clearance from host immune targeting REDWOOD CITY, Calif. & BOSTON – May 18, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting..."
05/09/2023 8-K Quarterly results
Docs: "Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet with $231.6 million in cash, cash equivalents and investments as of March 31, 2023 Redwood City, Calif. and BOSTON – May 9, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023. “We are excited about the continued clinical progress of our lead asset ADI-001,” said Chen Schor, President and Chief Executive Officer of Adicet. “In the s..."
03/15/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress • Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma ; Next data update expected in Q2 2023 • Announced preclinical data for differentiated chimeric antigen receptor and chimeric adaptor programs at The Society for Immunotherapy of Cancer 37th Annual Meeting and Adicet’s R&D Pipeline Event REDWOOD CITY, Calif. and BOSTON – March 15, 2023 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and ye..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
12/12/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1study during ASH Annual Meeting Company to host ADI-001 webcast event on December 11, 2022 at 9:00 a.m. ET On track to initiate a potentially pivotal program for ADI-001 in the first half of 2023 Strong balance sheet with $282.7 million in cash and cash equivalents as of September 30, 2022; Cash runway into first half of 2025 Company to host R&D webcast event detailing four new pipeline candidates on November 10, 2022 at 9:00 a.m. ET REDWOOD CITY, Calif. and BOSTON – November 8, 2022 – Adicet Bio, Inc. , a clinical stage biotechnology company discoverin..."
11/03/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/05/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches"
04/19/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001 Menlo Park, CA and Boston, MA – April 19, 2022 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, today announced the U.S. Food and Drug Administration has granted Fast Track Designation to its lead program ADI-001, an investigational therapy targeting CD20 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin’s lymphoma . ADI-001 is currently being evaluated in an ongoing dose escalation Phase 1study evaluating the safety and tolerability of ADI-001 for the potential treatment of NHL. The Fast Track Designation was granted based on ADI-001’s potential to address an unmet..."
03/24/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Change Order Number: 01 Project: Adicet Therapeutics 1000 Bridge Parkway Redwood City, CA 94065 Date: 21-Sep-21 Architect's Project No: Owner Architect □ □ To Contractor: Pressurized Change Per Western Allied and Adicet email dated 8/23/21 for the following work: Demolition of Installed Duet Upsizing Evs Upsize exhaust duct runs Upsize supply duct run Upsize grilles Subtotal $ 124,000.00 10% Profit, Overhead & Insurance $ 12,400.00 Total $ 136,400.00 The original Contract Sum was $ 13,625,700.00 The net change by previously authorized Change Orders $ 0.00 The Contract Sum prior to this Change Order was $ 13,625,700.00 The Contract Sum will be increased by this Change Order in the amount of $ 136,400.00 The new Contract Sum including this Change Order will be $ 13,762,100.00 T...",
"Change Order Number: 02 Project: Adicet Therapeutics 1000 Bridge Parkway Redwood City, CA 94065 Date: 7-Feb-22 Architect's Project No: Owner Architect □ □ To Contractor: Vivarium Modifications Per email correspondence with Charlie Penner on 2/3/22 for the following work: Demo $ 2,500.00 Electrical $ 8,000.00 HVAC & Plumbing $ 8,500.00 Fire Alarm $ 2,000.00 Fire Sprinklers $ 3,000.00 Frame & Drywall $ 10,000.00 Tape & Paint $ 4,500.00 Subtotal $ 38,500.00 10% Profit, Overhead & Insurance $ 3,850.00 Total $ 42,350.00 The original Contract Sum was $ 13,625,700.00 The net change by previously authorized Change Orders $ 136,400.00 The Contract Sum prior to this Change Order was $ 13,762,100.00 The Contract Sum will be increased by this Change Order in the amount of $ 42,350.00 The...",
"Change Order Number: 03 Project: Adicet Therapeutics 1000 Bridge Parkway Redwood City, CA 94065 Architect's Project No: Owner Architect □ □ To Contractor: Pressurized Change Adicet GxP Lab Rev 01 Demo $ 165,000.00 Demo existing finishes & reinstall $ 350,000.00 Walls $ 248,815.00 VCT and carpet flooring $ 9,000.00 HVAC $ 1,662,201.00 Electrical $ 567,000.00 Plumbing $ 499,644.00 Fire Sprinklers $ 61,237.00 Fire alarms $ 47,950.00 Doors $ 151,300.00 Lab casework, tables and lockers $ 134,250.00 Flooring labs $ 134,700.00 Equipment lift $ 130,000.00 Roofing $ 45,000.00 Structural steel $ 275,000.00 T-bar ceilings $ 130,320.00 FRP walls $ 75,000.00 Painting $ 61,580.00 Final Janitorial $ 7,000.00 General conditions & PM $ 90,000.00 Subtotal $ 485,017.00 10% Profit, Overhead & In..."
03/15/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress • Complete and near complete responses observed starting at lowest dose in interim findings from Phase 1study of ADI-001 in non-Hodgkin’s lymphoma ; additional interim clinical data expected in the first half of 2022 • Successfully raised $94.2 million in net proceeds through a public follow-on offering MENLO PARK, Calif. and BOSTON, Mass – March 15, 2022 – Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2021. “2022 marks an exc..."
02/03/2022 8-K Quarterly results
12/10/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/18/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors Menlo Park, CA and Boston, MA – November 18, 2021 – Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman M.D., Ph.D., to its Board of Directors. "Dr. Kauffman’s appointment brings a wealth of expertise to our board and will be invaluable as we advance the development of our pipeline of next-generation off-the-shelf, gamma-delta CAR-T therapies," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Kauffman is an industry veteran with considerable experience in oncology drug development and, notably, has been instrumental..."
11/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting Adicet’s allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the Company’s gamma delta T cell platform Preclinical findings demonstrated potent gamma delta CAR-T cell activation, cytotoxicity, tumor-specific homing, proliferation, and enhanced activity without evidence of graft versus host alloreactivity Menlo Park, CA and Boston, MA – November 12, 2021 – Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the presenta..."
11/10/2021 8-K Quarterly results
Docs: "Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates  On track to report top-line safety and tolerability data from ADI-001 Phase 1study in Non-Hodgkin's Lymphoma by year end  Announced collaboration with Twist Bioscience to accelerate discovery of gamma delta T cell cancer therapeutics and expand pipeline Menlo Park, CA and Boston, MA – November 10, 2021 – Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the third quarter ended September 30, 2021. “Over the third quarter, Adicet has made steady progress in advancing the first-in-human Phase 1 trial of our lead asset, AD..."
10/29/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
10/25/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "FOURTH AMENDMENT TO",
"AFFIRMATION AND AMENDMENT OF GUARANTY This AFFIRMATION AND AMENDMENT OF GUARANTY is made as of October 21, 2021 and effective as of October 19, 2021 , between Adicet Bio, Inc., a Delaware corporation and Pacific Western Bank ."
09/13/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
Docs: "Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates On track to report top-line interim data from ADI-001 Phase 1study in Non-Hodgkin's Lymphoma by the end of 2021 Menlo Park, CA and Boston, MA – August 12, 2021 – Adicet Bio, Inc. , a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported operational highlights and financial results for the second quarter ended June 30, 2021. “Adicet continues to build momentum over the second quarter, following the initiation of our Phase 1 trial of our lead asset ADI-001 in non-Hodgkin’s lymphoma and the completion of a successful capital raise earlier this year. We believe we are in a strong position to execute on key upco..."
07/30/2021 8-K Termination of a Material Definitive Agreement  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy